• 陕西省优秀期刊
  • 主办:陕西中医药大学

[1] CHEN FangyuanLI TianhaoZHANG LiyuanZHOU FengJIA RuiMA Jiangang,.Clinical Study on Combination of Qingjin Huatan Decoction and Cefazoxime in the Treatment of Pulmonary Infection after Chemotherapy in Advanced Non-Small Cell Lung Cancer [J]. Modern Traditional Chinese Medicine, 2024, (02): 53-58. [doi: 10.13424/j.cnki.mtcm.2024.02.010]
Copy

Clinical Study on Combination of Qingjin Huatan Decoction and Cefazoxime in the Treatment of Pulmonary Infection after Chemotherapy in Advanced Non-Small Cell Lung Cancer

References:

[1]West H,McCleod M,Hussein M,et al.Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130):a multicentre,randomised,open-label,phase 3 trial[J].The Lancet Oncology,2019,20(7):924-937.
[2]Garon EB,Hellmann MD,Rizvi NA,et al.Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab:results from the phase I KEYNOTE-001 study[J].Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology,2019,37(28):2518-2527.
[3]李鹏超,冯谢宇.桉柠蒎肠溶软胶囊联合哌拉西林他唑巴坦治疗晚期非小细胞肺癌化疗后伴肺部感染的临床疗效分析[J].癌症进展,2020,18(18):1899-1902.
[4]薛华,魏胜全,翟梅,等.脾多肽对晚期肺癌化疗患者肺部感染的疗效及免疫功能的影响[J].中华医院感染学杂志,2020,30(9):1355-1359.
[5]徐圣君,赵晓平.胸腺法新联合抗生素用于恶性肿瘤并发肺部感染的疗效观察[J].中国肿瘤临床与康复,2019,26(9):1073-1076.
[6]魏莲花,崔亚丽,张浩军,等.甘肃省74所医院肺泡灌洗液细菌分布及耐药性[J].中华医院感染学杂志,2021,31(22):3402-3406.
[7]倪海滨,马达,朱瑾,等.清金化痰汤联合抗生素治疗细菌性社区获得性肺炎的疗效[J].江苏医药,2019,45(7):730-732.
[8]李冰菲,付鹏亮,王东强,等.从“肺主皮毛”论治大疱性类天疱疮[J].中国中西医结合急救杂志,2019,26(1):125-126.
[9]朱丽娜.扶正祛邪方治疗多重耐药菌肺部感染临床研究[J].中西医结合研究,2021,13(4):230-233.
[10]支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2015,37(1):67-78.
[11]中华人民共和国卫生部.医院感染诊断标准(试行)[J].中华医学杂志,2001,81(5):314-320.
[12]孙颖,张玉龙,毛文娟,等.桂龙咳喘宁片联合抗菌药物对肺癌化疗后肺部感染的控制效果[J].现代生物医学进展,2017,17(27):5271-5274.
[13]何利,沈继录,王友梅.老年NSCLC合并肺部感染患者病原菌分布特点及影响因素[J].中国老年学杂志,2020,40(23):4975-4978.
[14]陈力津.肺癌患者化疗后肺部感染发生情况及影响因素研究分析[J].中国医学创新,2023,20(34):157-161.
[15]肖秀鹏,郭石平.肺癌术后肺部感染危险因素的系统评价与Meta分析[J].中国胸心血管外科临床杂志,2024,31(1):135-144.
[16]邱华平,李鹰飞,查国华.痰热清配合头孢唑肟对肺癌患者化疗后伴肺部感染的疗效与安全性评价[J].抗感染药学,2019,16(12):2173-2175.
[17]杨丹,梁靖.痰热清注射液联合头孢哌酮舒巴坦钠在肺癌化疗后肺部感染患者中的应用及血清hs-CRP、MMP-9水平的影响[J].航空航天医学杂志,2023,34(7):819-821,824.
[18]恒欣.血必净联合抗生素对肺癌化疗后肺部感染患者的临床疗效及其肺功能的影响[J].中国现代药物应用,2020,14(22):157-159.
[19]侯静静,郝蕊,杨秋敏.头孢他啶注射液辅助肺癌化疗对肺部感染的防治效果分析[J].国际医药卫生导报,2023,29(9):1249-1253.
[20]多玉峰.西药联合清金化痰汤对肺癌伴肺部感染40例血清炎症因子水平的影响[J].中国民族民间医药,2020,29(17):108-110.
[21]常文娟,权永志,王飞,等.麦冬地龙汤对肺癌化疗后并发肺部感染的效果[J].徐州医科大学学报,2022,42(2):102-105.
[22]巫小云,张丽,王甜甜.清金化痰汤辅助治疗肺癌合并肺部感染的效果及对KPS评分的影响[J].癌症进展,2019,17(10):1208-1211.
[23]李华,蒙建凤,唐丽娟.探讨肺癌与肺癌合并肺部感染患者血常规指标,血清炎性因子差异性[J].中国现代医生,2020,58(24):113-115.
[24]朱艳,叶淑芳,曹卓,等.早期肠内营养对肺癌患者肺部感染血清炎症因子与HMGB1的影响[J].中华医院感染学杂志,2019,29(3):62-65.
[25]Liu Y,Tian LL,You JY,et al.The predictive value of postoperative C-reactive protein (CRP),procalcitonin (PCT) and triggering receptor expressed on myeloid cells 1 (TREM-1) for the early detection of pulmonary infection following laparoscopic general anesthesia for cervical cancer treatment[J].Annals of Palliative Medicine,2021,10(4):4502-4508.
[26]郑守冰,王松炎,欧佳美.肺癌患者化疗后细菌感染患者C反应蛋白,降钙素原,中性粒细胞及NLR水平研究[J].广州医药,2020,51(3):62-65.
[27]胡慧婷,袁静芝,史清海,等.血清sCD14,HMGB1联合检测在肺部感染疾病中的临床诊断价值[J].国际检验医学杂志,2020,41(3):270-273.
[28]刘洁,王斐,杨侠,等.黄连解毒汤对重度颅脑损伤合并肺部感染患者血气指标和炎症因子影响分析[J].陕西中医,2020,41(3):318-320,349.
[29]申洁,雷蓉.百令胶囊治疗稳定期慢阻肺合并呼吸衰竭临床研究[J].现代中医药,2022,42(1):137-142.
[30]何孔琴,张业清,苏克雷,等.基于T淋巴细胞亚群探析中医药治疗老年肺炎研究现状[J].陕西中医药大学学报,2021,44(3):122-126.

Memo

基金项目:陕西省自然科学基础研究计划项目(2014JM4186)

Last Update: 2024-03-26
Copyright @ 2020 Editorial Office of Modern Traditional Chinese Medicine
 Address: Middle Section of Century Avenue, Xianyang, Shaanxi Province. Post Code: 712046
Tel: 029-38185250 Fax: 029-38185250 E-mail: shxzhzs@163.com Powered by: www.editorhome.cn